ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NICE fail to recommend AstraZeneca's cancer drug Olaparib on cost effectiveness basis
November 12, 2018Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib for women -
AstraZeneca’s selumetinib flops in thyroid cancer, adding to list of failures
July 30, 2018As it has been tussling over licensing checks and trying to gain a reprieve, AstraZeneca quietly announced in the midst of its quarterly update this morning that selumetinib has once again missed the mark in a cancer test.
Pharma Sources Insight January 2025
